Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Johns Hopkins University
- Principal investigator
- Sandeep Nayak, MD
- Start date
- 2024-02-08
- End date
- 2029-05-01
- Registry ID
- NCT06067737
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.